Dermatology

Dr. Ava Shamban Joins MedSpa Partners

Retrieved on: 
Wednesday, March 13, 2024
Vanity Fair, Beauty, Patient, Rest, Dermatology, Publication, Good Morning America, Women's health, Principal investigator, AVA, MSP, Extreme Makeover, Health, Television, Medical device

TORONTO, March 13, 2024 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Ava Shamban and her team at Ava MD to its top-tier North American medical aesthetics platform.

Key Points: 
  • TORONTO, March 13, 2024 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Ava Shamban and her team at Ava MD to its top-tier North American medical aesthetics platform.
  • Speaking on her reasons for joining MedSpa Partners, Dr. Shamban shared, "Like many of my colleagues, I was approached by numerous groups looking to acquire my practices.
  • MSP CEO Dominic Mazzone commented, "While Los Angeles can be associated with some of the more extreme approaches to cosmetic medicine, Ava Shamban is an icon for the kind of natural, individualized, and responsible medical aesthetics that MedSpa Partners promotes.
  • We couldn't be more excited to welcome Dr. Shamban and the exceptional team at Ava MD to MedSpa Partners."

Dermatology Imaging Devices Market Sees Strong 13% CAGR (2024-2030), Propelled by Rising Skin Cancer Cases

Retrieved on: 
Wednesday, March 13, 2024
Research, Diagnosis, OCT, Prevalence, Application, Partnership, Chapter Three, Hospital, Dermatology, AI, Skin, BDD, International, Google Images, FDA, USD, Health, Moles, Food

The global dermatology imaging devices market size is anticipated to reach USD 5.60 billion by 2030 and it is projected to grow at a CAGR of 13.09% from 2024 to 2030.

Key Points: 
  • The global dermatology imaging devices market size is anticipated to reach USD 5.60 billion by 2030 and it is projected to grow at a CAGR of 13.09% from 2024 to 2030.
  • The growing prevalence of skin disorders such as cancer, and inflammatory dermatoses, among others are the major contributing factors for market growth.
  • Dermatology imaging devices are efficient as they provide non-invasive, high-resolution visualization of skin lesions and other related conditions.
  • Technological advancements in dermatology imaging devices such as high-resolution images, integration with AI, 3D imaging are further expected to contribute to the market growth.

INTRODUCING BROWNKIND: SKINCARE DESIGNED FOR THE UNIQUE AGING SIGNS OF MELANIN-RICH SKIN

Retrieved on: 
Tuesday, March 12, 2024
Dark, Cream, Hyperpigmentation, Gooseberry, Beauty, Cleanser, Trial of the century, Phyllanthus emblica, Skin, Dermatology, Love, Pathology, Multimedia, Ageing, Cosmetics

NEW YORK, March 12, 2024 /PRNewswire/ -- Today, brownkind proudly announces the launch of its revolutionary skincare line, dedicated to preserving the inherently youthful appearance of brown skin in every shade. With a deep understanding of the dermatological science of melanin-rich skin types (in all tones, from the lightest expression of melanin to black), brownkind seeks to redefine the standard of skincare for the unique concerns and signs of aging for melanin-rich skin.

Key Points: 
  • With a deep understanding of the dermatological science of melanin-rich skin types (in all tones, from the lightest expression of melanin to black), brownkind seeks to redefine the standard of skincare for the unique concerns and signs of aging for melanin-rich skin.
  • "Skin of color has different signs of aging than white skin," said Dr. Gauri Desai.
  • It asks us to understand skin-care as an act of self-love, and to care for our skin with products that are scientifically designed for our specific concerns.
  • brownkind invites people of color to join us in celebrating the beauty of brown skin with our groundbreaking, melanin-targeted skincare line @brownkindskin.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
Tuesday, March 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
Tuesday, March 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

INMODE LTD. (NASDAQ: INMD) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against InMode Ltd.

Retrieved on: 
Monday, March 11, 2024
Court, Action Replay, Dentist, News, Advertising, Complaint, District court, Food and Drug Administration, Dermatology

If you purchased or acquired InMode common stock, and/or would like to discuss your legal rights and options please visit InMode Ltd.

Key Points: 
  • If you purchased or acquired InMode common stock, and/or would like to discuss your legal rights and options please visit InMode Ltd.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, LuxUrban, InMode, and Lantronix and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, March 10, 2024
Complaint, Analysis, Letter, Internet, New York Community Bank, Intelligence, Assumption, FDA, News, Internet of things, Dentist, Confidentiality, Injury, Transport, NYCB, ACL, City, Royalton Hotel, Food and Drug Administration, Signature, Result, EPS, Defendant, IOT, Dermatology, Category, P.C

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • NYCB is engaged in several national businesses, including multi-family lending, mortgage originations and servicing, and warehouse lending.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • Following these disclosures, Lantronix's stock price fell $1.89 per share, or 32.53%, to close at $3.92 per share on February 9, 2024.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024
Mohs surgery, Cancer, Carcinoma, SRT, Research, Pathology, FDA, Ageing, Food, RCM, Dermatology, Bed, Physiology, Epidermis, Vision, AAD, NMSC, Skin cancer, PAI, Patent, Patient, Tanning, United, American Academy, Medical imaging

GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.

Key Points: 
  • GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • “SkinCure Oncology,” Brandt continued, “is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • “Our new devices, subject to FDA Clearance,” Brandt said, “will offer cutting-edge technology in line with SkinCure Oncology’s vision for the future of dermatology.

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist

Retrieved on: 
Wednesday, March 6, 2024
Woman, Virology, ResearchGate, Preprint, Pain, Dermatology, Regression, Viral, Vaccine, Shingles, SOC, Research, Randomized controlled trial

BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist. Vaccines have been developed to prevent shingles, but there are few effective antiviral therapies capable of treating the outbreak while reducing the pain associated with the condition. The case study demonstrated a rapid response in the reduction of pain the size of the lesion area, due to a galectin antagonist.

Key Points: 
  • BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist.
  • Vaccines have been developed to prevent shingles, but there are few effective antiviral therapies capable of treating the outbreak while reducing the pain associated with the condition.
  • The case study demonstrated a rapid response in the reduction of pain the size of the lesion area, due to a galectin antagonist.
  • “This case study constitutes a proof of concept of the benefit of using a galectin antagonist in human shingles infection.

INMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, March 6, 2024
Court, Person, Dentist, FDA, Confidentiality, Injury, Complaint, Food and Drug Administration, Dermatology

InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.